Panel raised questions about Afrezza's commercial outlook, says Piper Jaffray Piper Jaffray believes the issues discussed as yesterday's FDA panel meeting raise questions regarding the commercial outlook for Afrezza. Piper believes FDA approval of the drug "seems inevitable" with yesterday's positive vote, but it sees challenges ahead and raised its price target for MannKind shares to only $2.00 from $1.50. It keeps an Underweight rating on the stock.
News For MNKD From The Last 14 Days
Check below for free stories on MNKD the last two weeks.
Stocks with call strike movement; MNKD SUNE MannKind (MNKD) January 17 call option implied volatility increased 6% to 79, SunEdison (SUNE) October 28 call option implied volatility increased 3% to 58 according to IVolatility.